AURA 株価分析 — Aura Biosciences Inc (Healthcare >> Biotechnology)
AURA に関するよくある質問
AURAのROE(自己資本利益率)は?
Aura Biosciences IncのROEは-104.80%です。
AURAの配当利回りは?
Aura Biosciences Incの配当利回りは0.00%です。
AURAの品質スコア(Quality Score)は?
当社のAIはAURAの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
AURAは今が買い時ですか?
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
AURAはどのセクターに属しますか?
Aura Biosciences IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
AURA AI Analysis Summary
Our AI summary for AURA: Aura Biosciences Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -104.80%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 7.15
Price
0.11
(1.56%)
Day Change
|
|
|---|
AURA, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
226
|
| Magic Formula Rank by ROE |
226
|
| Magic Formula Rank by ROIC |
71
GOOD
|
| Price | 7.15 |
| PBV / Sector |
6.79 / 44,022.72
|
| Earning Per Share | -1.10 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
3.09 M
GREAT
|
| Average 1W Daily Value |
2.49 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 07:59:51 |
| Symbol | AURA |
| Name | AURA BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 103.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 728.19 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 80 Guest Street, Boston, MA, United States, 02135
Phone: 617 500 8864
Website: https://www.aurabiosciences.com
Employees: 113
Sector: Healthcare >> Biotechnology
Description: Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google